(Q37866289)

24 August 2017

1 reference

title

Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges (English)

1 reference

24 August 2017

0 references

anti-retroviral agent

0 references

1 reference

2

1 reference

24 August 2017

B Ryan Phelps

1

1 reference

24 August 2017

1 June 2011

1 reference

24 August 2017

1 reference

24 August 2017

13

1 reference

24 August 2017

3

1 reference

24 August 2017

175-192

1 reference

https://scigraph.springernature.com/pub.10.2165/11587300-000000000-00000

24 August 2017

0 references

cites work

Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Management of paediatric HIV-1 resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Effect of food and pharmacokinetic variability on didanosine systemic exposure in HIV-infected children. Pediatric AIDS Clinical Trials Group Protocol 144 Study Team.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Bioavailability of once- and twice-daily regimens of didanosine in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetics and tolerance of zidovudine in preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

The clinical care of the HIV-1-infected infant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pediatric antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Efavirenz in the therapy of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetic evaluation of etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacotherapy of perinatal HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

An update on therapeutic drug monitoring for antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Toxicity of non-nucleoside analogue reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Clinical pharmacokinetics and pharmacodynamics of etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Current and future antiretroviral treatment options in paediatric HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Changes in indinavir exposure over time: a case study in six HIV-1-infected children.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetic optimization of antiretroviral therapy in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

High indinavir Cmin is associated with higher toxicity in patients on indinavir-ritonavir 800/100 mg twice-daily regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Global challenges in the development and delivery of paediatric antiretrovirals.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pediatric drugs--a review of commercially available oral formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

How do you improve compliance?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Taste and smell complaints in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Facilitating adherence to highly active antiretroviral therapy in children with HIV infection: what are the issues and what can be done?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Factors affecting adherence to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

The role of protease inhibitor therapy in children with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Adherence to medication regimens among children with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Antiretroviral pharmacokinetics in the paediatric population: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Optimizing oral medications for children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Practical approaches of taste masking technologies in oral solid forms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Trends in pharmaceutical taste masking technologies: a patent review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Gastrostomy tube insertion for improvement of adherence to highly active antiretroviral therapy in pediatric patients with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Oral medication administration: implications caused by capsule splitting.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Analysis of weight uniformity, content uniformity and 30-day stability in halves and quarters of routinely prescribed cardiovascular medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Weight variability of pharmacist-dispensed split tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Experiencing antiretroviral adherence: helping healthcare staff better understand adherence to paediatric antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

High Prevalence of Subtherapeutic Plasma Concentrations of Efavirenz in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Adherence issues in children and adolescents receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11587300-000000000-00000

Emerging antiretroviral drug interactions

21 January 2018

1 reference

12 December 2020

Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling

1 reference

12 December 2020

Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection.

1 reference

12 December 2020

Comparison of the palatability of the oral suspension of cefdinir vs. amoxicillin/clavulanate potassium, cefprozil and azithromycin in pediatric patients

1 reference

12 December 2020

Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen

1 reference

12 December 2020

Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).

1 reference

12 December 2020

Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications

1 reference

12 December 2020

Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021

1 reference

12 December 2020

Assessment of the palatability of antistaphylococcal antibiotics in pediatric volunteers

1 reference

12 December 2020

Increasing antiretroviral drug access for children with HIV infection

1 reference

12 December 2020

Pharmacologic aspects of new antiretroviral drugs

1 reference

12 December 2020

Methods for evaluating the taste of paediatric formulations in children: a comparison between the facial hedonic method and the patients' own spontaneous verbal judgement

1 reference

12 December 2020

Lack of medication dose uniformity in commonly split tablets

1 reference

12 December 2020

Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children

1 reference

12 December 2020

Pharmacokinetic Parameters of Nevirapine and Efavirenz in Relation to Antiretroviral Efficacy

1 reference

12 December 2020

Achieving adherence with antiretroviral medications for pediatric HIV disease

1 reference

12 December 2020

Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections

1 reference

12 December 2020

Treating an HIV-infected paediatric patient: an easy task?

1 reference

12 December 2020

Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.

1 reference

12 December 2020

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study

1 reference

12 December 2020

Maraviroc: pharmacokinetics and drug interactions

1 reference

12 December 2020

Interaction potential of etravirine with drug transporters assessed in vitro

1 reference

12 December 2020

Clinical inquiries. Which medications can be split without compromising efficacy and safety?

1 reference

12 December 2020

Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor

1 reference

12 December 2020

Pancreatitis in human immunodeficiency virus-infected children receiving dideoxyinosine

1 reference

12 December 2020

10.2165/11587300-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21500872

Dimensions Publication ID

24 August 2017

0 references

1 reference

PubMed ID

21500872